The Korean Journal of Gastroenterology (대한소화기학회지)

The Korean Society of Gastroenterology (대한소화기학회)
권호 표지
DOI QR코드

DOI QR Code

Review of the Clinical Practice Guidelines for Irritable Bowel Syndrome in Korea, 2017 Revised Edition

2017 과민성장증후군의 임상진료지침 개정안 소개

  • Jung, Hye-Kyung (Department of Internal Medicine, College of Medicine, Ewha Womans University)
  • 정혜경 (이화여자대학교 의과대학 내과학교실)
  • Received : 2018.10.01
  • Accepted : 2018.11.03
  • Published : 2018.11.25
⟨ Previous Next ⟩

Abstract

This guidance is an updated version of the irritable bowel syndrome (IBS) guidelines based on evidence-based medicine. IBS is a common chronic gastrointestinal syndrome that occurs in approximately 10% of the population and causes chronic abdominal pain as well as bowel habit changes, such as stool frequency or consistency. The final diagnosis of IBS is based on the exclusion of organic diseases that would explain the symptoms and the absence of endoscopic abnormalities. IBS can reduce the quality of life and cause a major disease burden, such as repeated examinations and continuous drug use, by mistaking organic diseases including malignancy. The major changes are as follows: 1) when to perform a colonoscopy under the impression of IBS; 2) effect of a low-fermentable oligosaccharides, disaccharides, monosaccharides, and polyol diet; 3) impact of probiotics in IBS; and 4) role of antibiotics in IBS. The Korean Society of Neurogastroenterology and Motility recently updated these guidelines to support physicians for qualified medical services and reduce the socioeconomic burden of IBS.

Keywords

References

  1. Spiller R, Aziz Q, Creed F, et al. Guidelines on the irritable bowel syndrome: mechanisms and practical management. Gut 2007;56:1770-1798. https://doi.org/10.1136/gut.2007.119446
  2. Hookway C, Buckner S, Crosland P, Longson D. Irritable bowel syndrome in adults in primary care: summary of updated NICE guidance. BMJ 2015;350:h701.
  3. Mearin F, Lacy BE. Diagnostic criteria in IBS: useful or not? Neurogastroenterol Motil 2012;24:791-801. https://doi.org/10.1111/j.1365-2982.2012.01992.x
  4. Lee SY, Lee KJ, Kim SJ, Cho SW. Prevalence and risk factors for overlaps between gastroesophageal reflux disease, dyspepsia, and irritable bowel syndrome: a population-based study. Digestion 2009;79:196-201. https://doi.org/10.1159/000211715
  5. Lee YY, Waid A, Tan HJ, Chua AS, Whitehead WE. Rome III survey of irritable bowel syndrome among ethnic Malays. World J Gastroenterol 2012;18:6475-6480. https://doi.org/10.3748/wjg.v18.i44.6475
  6. Siah KT, Wong RK, Chan YH, Ho KY, Gwee KA. Prevalence of irritable bowel syndrome in Singapore and its association with dietary, lifestyle, and environmental factors. J Neurogastroenterol Motil 2016;22:670-676. https://doi.org/10.5056/jnm15148
  7. Miwa H. Prevalence of irritable bowel syndrome in Japan: internet survey using Rome III criteria. Patient Prefer Adherence 2008;2:143-147.
  8. Buono JL, Mathur K, Averitt AJ, Andrae DA. Economic burden of inadequate symptom control among US commercially insured patients with irritable bowel syndrome with diarrhea. J Med Econ 2017;20:353-362. https://doi.org/10.1080/13696998.2016.1269016
  9. Lee OY, Yoon CO. Review : evidence based guideline for diagnosis and treatment : diagnostic guideline for irritable bowel syndrome. Kor J Neurogastroenterol Motil 2005;11:30-35.
  10. Park HJ. Review : evidence based guideline for diagnosis and treatment : therapeutic guideline for irritable bowel syndrome. Kor J Neurogastroenterol Motil 2005;11:36-43.
  11. Park JH, Byeon JS, Shin WG, et al. Diagnosis of irritable bowel syndrome: a systematic review. Korean J Gastroenterol 2010;55:308-315. https://doi.org/10.4166/kjg.2010.55.5.308
  12. Kwon JG, Park KS, Park JH, et al. Guidelines for the treatment of irritable bowel syndrome. Korean J Gastroenterol 2011;57:82-99. https://doi.org/10.4166/kjg.2011.57.2.82
  13. Song KH, Jung HK, Kim HJ, et al. Clinical practice guidelines for irritable bowel syndrome in Korea, 2017 revised edition. J Neurogastroenterol Motil 2018;24:197-215. https://doi.org/10.5056/jnm17145
  14. Hammer J, Eslick GD, Howell SC, Altiparmak E, Talley NJ. Diagnostic yield of alarm features in irritable bowel syndrome and functional dyspepsia. Gut 2004;53:666-672. https://doi.org/10.1136/gut.2003.021857
  15. Whitehead WE, Palsson OS, Feld AD, et al. Utility of red flag symptom exclusions in the diagnosis of irritable bowel syndrome. Aliment Pharmacol Ther 2006;24:137-146. https://doi.org/10.1111/j.1365-2036.2006.02956.x
  16. Black TP, Manolakis CS, Di Palma JA. "Red flag" evaluation yield in irritable bowel syndrome. J Gastrointestin Liver Dis 2012;21:153-156.
  17. Gibson PR, Shepherd SJ. Food choice as a key management strategy for functional gastrointestinal symptoms. Am J Gastroenterol 2012;107:657-666; quiz 667. https://doi.org/10.1038/ajg.2012.49
  18. Iacovou M, Tan V, Muir JG, Gibson PR. The low FODMAP diet and its application in East and Southeast Asia. J Neurogastroenterol Motil 2015;21:459-470. https://doi.org/10.5056/jnm15111
  19. Halmos EP, Power VA, Shepherd SJ, Gibson PR, Muir JG. A diet low in FODMAPs reduces symptoms of irritable bowel syndrome. Gastroenterology 2014;146:67-75.e5. https://doi.org/10.1053/j.gastro.2013.09.046
  20. Staudacher HM, Lomer MC, Anderson JL, et al. Fermentable carbohydrate restriction reduces luminal bifidobacteria and gastrointestinal symptoms in patients with irritable bowel syndrome. J Nutr 2012;142:1510-1518. https://doi.org/10.3945/jn.112.159285
  21. Staudacher HM, Whelan K, Irving PM, Lomer MC. Comparison of symptom response following advice for a diet low in fermentable carbohydrates (FODMAPs) versus standard dietary advice in patients with irritable bowel syndrome. J Hum Nutr Diet 2011;24:487-495. https://doi.org/10.1111/j.1365-277X.2011.01162.x
  22. Pimentel M, Chow EJ, Lin HC. Normalization of lactulose breath testing correlates with symptom improvement in irritable bowel syndrome. A double-blind, randomized, placebo-controlled study. Am J Gastroenterol 2003;98:412-419.
  23. Sharara AI, Aoun E, Abdul-Baki H, Mounzer R, Sidani S, Elhajj I. A randomized double-blind placebo-controlled trial of rifaximin in patients with abdominal bloating and flatulence. Am J Gastroenterol 2006;101:326-333. https://doi.org/10.1111/j.1572-0241.2006.00458.x
  24. Pimentel M, Park S, Mirocha J, Kane SV, Kong Y. The effect of a nonabsorbed oral antibiotic (rifaximin) on the symptoms of the irritable bowel syndrome: a randomized trial. Ann Intern Med 2006;145:557-563. https://doi.org/10.7326/0003-4819-145-8-200610170-00004
  25. Pimentel M, Lembo A, Chey WD, et al. Rifaximin therapy for patients with irritable bowel syndrome without constipation. N Engl J Med 2011;364:22-32. https://doi.org/10.1056/NEJMoa1004409
  26. Lembo A, Pimentel M, Rao SS, et al. Repeat treatment with rifaximin is safe and effective in patients with diarrhea-predominant irritable bowel syndrome. Gastroenterology 2016;151:1113-1121. https://doi.org/10.1053/j.gastro.2016.08.003
  27. Chang L, Lembo A, Sultan S. American gastroenterological association institute technical review on the pharmacological management of irritable bowel syndrome. Gastroenterology 2014;147:1149-1172.e2. https://doi.org/10.1053/j.gastro.2014.09.002
  28. Ford AC, Quigley EM, Lacy BE, et al. Efficacy of prebiotics, probiotics, and synbiotics in irritable bowel syndrome and chronic idiopathic constipation: systematic review and meta-analysis. Am J Gastroenterol 2014;109:1547-1561; quiz 1546, 1562. https://doi.org/10.1038/ajg.2014.202
  29. Yoon JS, Sohn W, Lee OY, et al. Effect of multispecies probiotics on irritable bowel syndrome: a randomized, double-blind, placebo-controlled trial. J Gastroenterol Hepatol 2014;29:52-59. https://doi.org/10.1111/jgh.12322
  30. Cha BK, Jung SM, Choi CH, et al. The effect of a multispecies probiotic mixture on the symptoms and fecal microbiota in diarrhea-dominant irritable bowel syndrome: a randomized, double-blind, placebo-controlled trial. J Clin Gastroenterol 2012;46:220-227. https://doi.org/10.1097/MCG.0b013e31823712b1
  31. Choi CH, Jo SY, Park HJ, Chang SK, Byeon JS, Myung SJ. A randomized, double-blind, placebo-controlled multicenter trial of saccharomyces boulardii in irritable bowel syndrome: effect on quality of life. J Clin Gastroenterol 2011;45:679-683. https://doi.org/10.1097/MCG.0b013e318204593e
  32. Sinn DH, Song JH, Kim HJ, et al. Therapeutic effect of Lactobacillus acidophilus-SDC 2012, 2013 in patients with irritable bowel syndrome. Dig Dis Sci 2008;53:2714-2718. https://doi.org/10.1007/s10620-007-0196-4

Cited by

  1. The Effect of Complex Korean Medical Treatment with Acupotomy on Irritable Bowel Syndrome: A Case Report vol.37, pp.1, 2018, https://doi.org/10.13045/jar.2019.00311